The complex patent dispute between Seagen Inc. and Daiichi Sankyo Inc. reached a significant juncture as the Patent Trial and Appeal Board (PTAB) found all of Seagen’s claims for the patent number: 10,808,039, invalid. This patent involved antibody-drug conjugate technology (ADC), a critical component in the development of advanced cancer treatments. Seagen’s claims were rejected on the grounds of lack of enablement, lack of written description, and anticipation, according to Ryan Hagglund at Loeb & Loeb.
The latest PTAB decision marks only one episode in a broader, multifaceted legal struggle over ADC technology that extends to involve pharmaceutical giant, AstraZeneca. This ongoing legal battle has wide-ranging implications for the pharmaceutical industry and stands as an indicator of the tense competition in the field of ADC technology.
The case is expected to proceed to a director review, further extending this protracted legal saga. As this case evolves, legal professionals and stakeholders in the pharmaceutical industry will be closely monitoring its development and eventual outcomes.
For more detailed coverage and analysis of the PTAB’s decision in the Seagen cancer drug patent dispute, promote viewing of the original article published on Law360 here.